# The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation

Study · id `cardio:ct-nct01423188` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01423188](<https://clinicaltrials.gov/study/NCT01423188>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01423188

Browse, organ or system: Heart; Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 176 participants.

## Technical summary

Registry record NCT01423188. Randomized; triple masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2012-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 176 participants (enrolled count; ClinicalTrials.gov record NCT01423188, source copy `cardio:ctgov-nct01423188-2012-09-20`, retrieved 2026-10-26)
- Start date: 2011-08 (registry gives no type) (ClinicalTrials.gov record NCT01423188, source copy `cardio:ctgov-nct01423188-2012-09-20`, retrieved 2026-10-26)
- Primary completion: 2012-06 (actual) (ClinicalTrials.gov record NCT01423188, source copy `cardio:ctgov-nct01423188-2012-09-20`, retrieved 2026-10-26)
- Completion: 2012-08 (actual) (ClinicalTrials.gov record NCT01423188, source copy `cardio:ctgov-nct01423188-2012-09-20`, retrieved 2026-10-26)
- Countries: South Africa (ClinicalTrials.gov record NCT01423188, source copy `cardio:ctgov-nct01423188-2012-09-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01423188-2012-09-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation
- Acronym: SUSTAIN
- Condition: Coronary Artery Disease
- Condition: Dyslipidemia
- Intervention (Drug): RVX000222
- Intervention (Drug): Placebo RVX000222
- Lead sponsor: Resverlogix Corp
- Lead sponsor class: INDUSTRY
- Collaborator: The Cleveland Clinic
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Resverlogix Corp (`cardio:org-resverlogix-corp`)
- Registry lists this organization as a collaborator: The Cleveland Clinic (`cardio:org-the-cleveland-clinic`)

## Provenance

Content hash: 78fa5340a879f0f79fe1b0ebf2b74bb730fbc5971fbd7b7e88729655f85ff89f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
